Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of BoNT/A-DP versus placebo for glabellar lines with open-label extension
2018-003983-30Phase 3Completed
- Sponsor
- Croma-Pharma
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum neurotoxin type A-DP in glabellar furrowing (2 arms), sponsored by Croma-Pharma. Primary endpoint: Composite responder rate at maximum frown at week 4. Started Mar 2019; status: completed.
02
Drugs
botulinum neurotoxin type A-DP
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2018-003983-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003983-30.